铁亡有助于多发性硬化症,其药理向抑制了实验性疾病进展
Emily Van San1,2, Angela C Debruyne3, Geraldine Veeckmans4
1Department of Biomedical Molecular Biology, Ghent university, Ghent, Belgium.
Cell death and differentiation
|August 4, 2023
概括
铁,一种涉及铁的细胞死亡形式,有助于多发性硬化症 (MS) 的进展. 在临床前模型中,通过减少疾病严重程度,抑制铁灭对治疗多发性硬化有希望.
科学领域:
- 神经免疫学 神经免疫学
- 细胞生物学 细胞生物学
- 病理学 病理学 病理学
背景情况:
- 多发性硬化症 (MS) 是一种慢性自身免疫性中枢神经系统疾病,导致脱髓化,轴突损伤和神经缺陷.
- 目前的多发性硬化症疗法主要使用免疫抑制,缺乏针对细胞死亡引起的损伤的特定治疗方法.
- 多发性硬化症的发病包括炎症和细胞死亡的自强化循环.
研究的目的:
- 为了研究铁灭的作用,一个铁催化调节细胞死亡 (RCD),在多发性硬化症 (MS) 的发病.
- 在临床前MS模型中评估向铁亡的治疗潜力.
主要方法:
- 分析活跃和慢性MS病变和脑脊液 (CSF) 的铁亡标志物.
- 在多发性硬化患者样本中评估铁含量,过氧化脂和脂质降解产物.
- 在复发性复发性多发性硬化症的临床前模型中对铁灭抑制剂 (UAMC-3203) 的评估.
主要成果:
- 在MS病变和CSF中发现了铁的证据,包括铁含量升高,过氧化脂和脂质降解产物.
- 在临床前MS模型中,用铁灭抑制剂UAMC-3203治疗显著延迟了复发并改善了疾病进展.
结论:
- 铁亡被确定为一种有害和可向的因素,有助于MS疾病的进展.
- 向铁死是一种新的MS治疗策略,可能补充现有的免疫抑制治疗方法.
更多相关视频
相关概念视频
Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
Parkinson's Disease: Overview
598
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
598
Parkinson's Disease: Treatment
299
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
299
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K


